The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
MSF has transitioned all patients with type 1 diabetes in our clinics in Lebanon from vials to insulin pens. Here are the stories from patients and staff about how the move has improved both medical outcomes and patients’ quality of life.
